We evaluated the efficacy and safety of the fixed dose of 5000 IU unfractionated heparin (UFH) represented as peak activated clotting time (ACT) according to the body mass index (BMI) tertiles in patients undergoing diagnostic transradial coronary angiography (TRCA). A total of 422 patients were included in the present study, 84 in the normal weight group, 218 in the overweight group, and the 120 in the grades 1 and 2 obesity groups. Radial artery occlusion (RAO) was observed in 29 (6.8%) patients and the hematoma was observed in 43 (10.1%) patients. The rate of RAO and hematoma did not differ across the BMI tertiles (P = .749 and P = .066). Also, peak ACT and procedure duration did not differ between the study groups (P = .703 and P = .999). The only independent predictor of hematoma was sheath/radial artery diameter (P = .011) and the independent predictors for RAO were peak ACT, sheath/radial artery diameter, and procedure duration (P = .001, P = .028, and P < .001, respectively). In conclusion, a fixed dose of 5000 IU UFH is safe and effective regardless of the BMI in diagnostic TRCA procedure.
CrudenNLTehCHStarkeyIRNewbyDE. Reduced vascular complications and length of stay with transradial rescue angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv. 2007;70(5):670–675.
2.
SpauldingCLefèvreTFunckF. Left radial approach for coronary angiography: results of a prospective study. Cathet Cardiovasc Diagn. 1996;39(4):365–370.
3.
KoutouzisMLagerqvistBJamesS. Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Heart. 2011;97(18):1484–1488.
4.
StegPGMehtaSJollyS. Fondaparinux with unfractionated heparin during revascularization in acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux. Am Heart J. 2010;160(6):1029–1034.
5.
WalengaJMLymanGH. Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):1–18.
6.
BriegerDColletJPSilvainJ. Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention. Catheter Cardiovasc Interv. 2011;77(2):182–190.
7.
HattersleyPG. The activated coagulation of whole blood as a routine pre-operative screening test. Calif Med. 1971;114(5):15–18.
8.
BellaicheALNielsenPFKirkegaardH. Is the ACT two minutes after heparin injection reliable?Perfusion. 2011;26(4):322–326.
9.
HeresEKSpeightKBenckartDMarquezJGravleeGP. The clinical onset of heparin is rapid. Anesth Analg. 2001;92(6):1391–1395.
10.
GravleeGPAngertKCTuckerWYCaseLDWallenhauptSLCordellAR. Early anticoagulation peak and rapid distribution after intravenous heparin. Anesthesiology. 1988;68(1):126–129.
11.
RineyJNHollandsJMSmithJRDealEN. Identifying optimal initial infusion rates for unfractionated heparin in morbidly obese patients. Ann Pharmacother. 2010;44(7-8):1141–1151.
12.
BarlettaJFDeYoungJLMcAllenKBakerRPendletonK. Limitations of a standardized weight-based nomogram for heparin dosing in patients with morbid obesity. Surg Obes Relat Dis. 2008;4(6):748–753.
13.
BauerSROuNNDreesmanBJ. Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: a retrospective cohort study. Mayo Clin Proc. 2009;84(12):1073–1078.
BurzottaFTraniCMazzariMA. Vascular complications and access crossover in 10,676 transradial percutaneous coronary procedures. Am Heart J. 2012;163(2):230–238.
16.
BertrandOF. Acute forearm muscle swelling post transradial catheterization and compartment syndrome: prevention is better than treatment!Catheter Cardiovasc Interv. 2010;75(3):366–368.
17.
HuangFYHuangBTWangPJ. Gender disparity in the safety and efficacy of radial and femoral access for coronary intervention: a systematic review and meta-analysis. Angiology. 2016;67(9):810–819.
18.
RathoreSStablesRHPauriahM. A randomized comparison of TR band and radistop hemostatic compression devices after transradial coronary intervention. Catheter Cardiovasc Interv. 2010;76(5):660–667.
19.
OgdenCLCarrollMDCurtinLRMcDowellMATabakCJFlegalKM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295(13):1549–1555.
20.
FlegalKMCarrollMDOgdenCLJohnsonCL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288(14):1723–1727.
21.
JanmahasatianSDuffullSBAshSWardLCByrneNMGreenB. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051–1065.
22.
HanleyMJAbernethyDRGreenblattDJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71–87.
23.
YeeDLO’BrienSHYoungG. Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients. Clin Pharmacokinet. 2013;52(11):967–980.
24.
GallagherDVisserMSepulvedaDPiersonRNHarrisTHeymsfieldSB. How useful is body mass index for comparison of body fatness across age, sex and ethnic groups?Am J Epidemiol. 1996;143(3):228–239.
25.
HongXShanPRHuangWJ. Influence of body mass index on the activated clotting time under weight-based heparin dose. J Clin Lab Anal. 2016;30(2):108–113.
26.
SchwiesowSJWessellAMSteyerTE. Use of a modified dosing weight for heparin therapy in a morbidly obese patient. Ann Pharmacother. 2005;39(4):753–756.
